Measles-Associated CNS Complications: A Review

Reena Jain1  Roosy Aulakh1

1Department of Pediatrics, Government Medical College and Hospital, Chandigarh, India

Address for correspondence Roosy Aulakh, MD, Department of Pediatrics, Government Medical College and Hospital, Chandigarh 160030, Sector 32B, India (e-mail: droachy@gmail.com).

Abstract

Keywords  ► measles virus
► primary measles encephalitis
► acute post infectious measles encephalomyelitis
► measles inclusion body encephalitis
► subacute sclerosing pan encephalitis

Measles virus infection is a common infectious disease of childhood, incidence of which is still high in developing countries. Other than the morbidity associated with the acute systemic infection, the measles virus can cause serious fatal neural complications. It can either enter the brain leading to acute encephalitis like primary measles encephalitis and acute post infectious measles encephalomyelitis or it may persist in brain cells (as mutated virus) leading to long-term neurodegenerative diseases like measles inclusion body encephalitis and subacute sclerosing pan encephalitis. The patho-clinical features, treatment, and the outcomes of these complications are different and should be identified in time for early diagnosis and management.

Introduction

Measles is a highly contagious infection caused by measles virus, which belong to paramyxoviridae family. The virus enters the human body (its sole reservoir) via respiratory system in air droplets form. It targets the macrophages and dendritic cells in lungs which express SLAM receptors.1 These cells then migrate to lymph nodes and transmit the infection to lymphocytes expressing SLAM receptors, hence causing viremia. In later stage, the infected cells transmit the infection to nectin 4 expressing epithelial cells in respiratory tract, from where virions are shed in mucus and spread air drop infection through coughing.2 Patient develops various symptoms during acute phase of measles infection like fever, cough, coryza, conjunctivitis, nasal congestion followed by a morbilliform rash, and koplik spots over buccal mucosa (in 70% cases).3,4 Measles virus infection also causes immunocompromised state in the host, making the host susceptible for secondary infections.5 Other than this, measles infection can lead to several complications including diarrhea, otitis media, pneumonia, CNS infections and sequelae, blindness and hearing loss.6,6 The morbidity and mortality related to measles is higher in developing countries owing to under nutrition, large populations, inaccessibility of health care and vaccination.7 This review is undertaken to highlight the CNS measles infections and associated morbidity.

Measles virus affects the CNS either during active infection or after the infection has become inactive.6 The CNS complications are: (1) primary measles encephalitis (PME), (2) acute post infectious measles encephalomyelitis (APME), (3) measles inclusion body encephalitis (MIBE), and (4) subacute sclerosing pan encephalitis (SSPE). The neuropathogenesis, host immune status, and clinical settings are different, but all involves brain-virus and immune interactions that lead to severe morbidity and mortality as discussed ahead.

Current Epidemiology

Measles is one of the most contagious vaccine preventable disease. The global incidence of measles infection decreased
Table 1 Incidence of measles related CNS complications after natural measles infection and after vaccination

| Disease          | Incidence after measles infection | Incidence after vaccination | Morbidity and mortality                                      |
|------------------|----------------------------------|-----------------------------|--------------------------------------------------------------|
| PME              | 1-3/1,000                        | <1 per 10,00,000 less fulminant | Mortality: 10 to 15%, permanent neurological sequelae in 25%, with epilepsy and intellectual disability |
| APME             | 1/1,000                          | 1–2/10,00,000 less fulminant | Some have a full recovery, while few are left with substantial neurological sequelae |
| MIBE             | RARE (only in immunocompromised patients) | <1 per 10,00,000 | Mortality: 75% Rest have poor neurological outcomes |
| SSPE             | 4-11/1,00,000                    | 0                           | Mortality: 100%                                               |

Abbreviations: APME, acute post infectious measles encephalomyelitis; MIBE, measles inclusion body encephalitis; PME, primary measles encephalitis; SSPE, sclerosing pan encephalitis.

How Does Measles Virus Enter the Brain?

The entry of measles virus in brain still remains unclear, however, different models have shown different mechanisms for measles-related CNS infection:

1. Via receptors: SLAM receptor is the main receptor for morbilliform virus infection including both canine distemper virus (CDV) and measles virus. This receptor is expressed on dendritic cells, thymocytes, lymphocytes, and macrophages in humans. In CDV-infected dogs SLAM receptor expression increases in epithelium of many organs like lungs, gastrointestinal and urinary tracts, however, these detected SLAM positive cells are immune or inflammatory cells. The brain cells are negative for SLAM expression, still various brain cells are infected with CDV, suggesting other receptors role for viral spread in CNS. Recently nectin-4 receptor expression has been reported in various CNS cells (purkinje cells, neurons, ependymal cells, and choroid plexus cells) in dogs suggesting it contributes to CDV neuropathogenicity, while it is hardly detected in human brain cells. Astrocytes in dog’s brain were found to be infected by CDV leading to demyelination, although they do not express nectin-4. These findings further suggest the role of an unknown receptor in neuropathogenicity of CDV. Recently nectin 1 receptors have been suggested to play a role in CDV and measles neuroinvasion. It has been postulated that viral RNP enters the nectin 1 expressing neuronal cells (olfactory bulb/brain parenchyma) via transcellular endocytosis from nectin four positive cells in nasal turbinate or meninges.

2. Mutations in virus: It has been hypothesized that various mutations of measles virus may help in neuroinvasion without any need of receptors. These mutated virus particles have been isolated from either autopsy or biopsy of brain tissue of patients of complicated measles infection. The reported incidence for SSPE is 1:10,000 to 20,000 measles cases, it generally occurs after a long latent period of measles infection and is associated with 100% mortality.

3. Measles virus tropism via hematogenous route: via infecting the endocytes at blood–brain barrier and then passing in CNS or via virus-infected lymphocytes entering brain through BBB.

Measles-Associated Different CNS Complications: Associated Morbidity and Mortality

There has been a considerable controversy regarding the mechanism of measles encephalitis. Whether it is due to direct CNS infection or immune mediated? It has been suggested that early CNS symptoms (within a week of measles infection) can only be explained with direct neuroinvasion of virus and the late symptoms with autoimmune mechanism. Some investigators failed to demonstrate viral proteins or RNA in the brain of measles encephalitis patients while, others recovered measles virus from brain parenchyma and CSF of such patients.
The clinical profile and characteristics of measles virus in each disease are discussed below and summarized in Table 3.

Primary Measles Encephalitis (PME)
The measles virus directly infects CNS during acute measles infection in a previously healthy child, leading to measles encephalitis. The virus replicates in brain cells and leads to injury of neurons, which further causes lymphocytic infiltration in brain parenchyma, meninges, and CSF, hence, the infectious measles virus can be detected from brain cells and CSF.

It occurs in immunocompetent, unvaccinated or partially vaccinated measles-infected patients (more common in children than adults) with a frequency of 1 to 3 per 1,000 cases. The symptoms of encephalitis generally develop during the exanthema phase or within a week of measles prodrome. The child presents with fever, headache, irritability encephalopathy (altered mental status), seizures and involuntary movements or motor deficits (hemiplegia/paraplegia), and coma. Child may have features of raised ICT due to brain edema.

The long-term neurological sequelae leads to hemi or paraplegia, intellectual disability, recurrent seizures, and deafness. The diagnosis of PME is mostly clinical. CSF examination shows marked lymphocytic pleocytosis and mildly elevated protein. Neuroimaging shows edema and/or focal signal changes in white matter, putamen, caudate nucleus, and thalamus. The viral RNA can be detected in CSF via real time PCR.

The treatment of PME is mainly supportive including continuous vitals monitoring, anticonvulsants, measures for raised ICT (mannitol or hypertonic saline), antipyretics and fluids and electrolytes management. Ribavirin has shown anti-measles properties in vitro and has been given in complicated measles cases via intravenous or aerosol routes. However, it has not been approved for measles encephalitis by U.S. FDA. Controlled trials need to be done to prove the efficacy of ribavirin in measles. Mortality is observed in around 10 to 15% of patients and long-term neurological sequel in 25% of patients.

Acute Post Measles Encephalitis
It is also referred to as acute measles encephalitis (AME), acute demyelinating encephalomyelitis (ADEM), or post infectious encephalitis (PIE) or acute disseminated encephalomyelitis. The encephalitis is immune mediated unlike PME which is due to direct viral invasion. The molecular mimicry has been suggested as the mechanism for the development of APME. Circulating antibodies react with the myelin basic protein of oligodendrocytes, causing inflammation and dysfunction in CNS. APME causes lesions in both grey and white matter, leading to perivenular inflammation and demyelination. Immunoglobulin titers in CSF as compared to that in the serum do not increase, suggesting less synthesis of antibodies in CSF. Myelin basic protein concentrations are increased in CSF and nearly 50% of the patients show lymphocytic proliferative responses to myelin basic protein. It is primarily an immune-mediated demyelinating disease, however, the role of myelin reactive antibodies is still unclear. Any rise in myelin reactive antibodies was not detected by either ELISA or RIA in patients with APME, while in animal models a rise in myelin reactive antibodies along with pathology similar

| Protein | Mutation | Effect | Disease |
|---------|----------|--------|---------|
| M protein | Biased hypermutation of M protein (uridine to cysteine substitution) | More fusogenic phenotype without budding making it more suitable for CNS infection | SSPE and MIBE |
| RNA mutation causing low expression of M protein | | | |
| F protein | HRC domain (T461I, A440P, N462S, N465S), HRN domain (G168R, E170G), (S262G), cytoplasmic tail domain (RS20C, L550P), F2 subunit of F protein, F extracellular domain (T461L, S103I/ N462S/N465S) | Hyperfusogenic F protein which allows entry in brain without receptors | SSPE |
| HRC domain L454W | Highly unstable and hyperfusogenic F protein, not requiring receptor for invasion | MIBE |
| H protein | Substitution mutations cytoplasmic tail (R7Q), stalk domain (R62Q), and five blade of the head domain (D530E), Cterminus elongation of the H protein due to single-point mutation at the stop codon | Contributes neurovirulence impact binding, targeting | SSPE |
| Mutations in H gene of MIBE | Less frequently documented | MIBE |
| N, P, and L proteins | | SSPE and MIBE |

Abbreviations: CNS, central nervous symptom; MIBE, Measles Inclusion Body Encephalitis; RNA, ribonucleic acid; SSPE, sclerosing pan encephalitis.
Table 3 Differentiating features of measles associated CNS complications\(^\text{17,18,20,21}\)

|                      | PME               | APME              | MIBE                              | SSPE                              |
|----------------------|-------------------|-------------------|-----------------------------------|-----------------------------------|
| Measles infection    | Active measles infection | Post infectious   | Active measles infection in patients who are immunosuppressed | Measles infection early childhood, no active infection now. |
| (active/passive)     |                   |                   |                                   |                                   |
| Temporal relation    | During acute exanthem phase | During resolution phase or weeks/months after measles infection or vaccination? | Onset within a year of infection or measles vaccination? | Occurs after 3-20 years of infection although shorter latency periods reported recently |
| of onset with         |                   |                   |                                   |                                   |
| measles infection     |                   |                   |                                   |                                   |
| Mechanism of         | Measles virus enters the brain causing lymphocytic infiltration | Molecular mimicry mediated immune response | Persistence of primary measles infection | Persistence of mutated measles virus |
| disease              |                   |                   |                                   |                                   |
| Age group            | More common in children than in adults | Most common in children and adolescents, rare in adults | Any age, More common in children and young adults | Usually 8-11 years, can be seen in toddlers and adults |
| Clinical features    | Fever, headache, irritability encephalopathy, seizures, involuntary movements or motor deficits and coma | Encephalitis (seizures, altered sensorium, raised ICT), myelitis (back pain and bladder and bowel dysfunction, hyporeflexia), ataxia, optic neuritis | No rash, encephalopathy, refractory seizures, motor deficits | Behavioral problems, motor dysfunction, spasticity, myoclonic jerks, ocular involvement |
| EEG                  | Focal or generalized epileptiform discharges or diffuse slowing | Either normal or non-specific changes | Focal or generalized epileptiform discharges or diffuse slowing | Burst suppression, diffuse slowing |
| Neuroimaging         | Focal signal changes on T2 images and edema | Multifocal hyperintensities in brain and spinal cord, brain edema, demyelination | Initially normal, later edema, atrophy or ventriculomegaly can be seen | Hyperintensities in cerebral cortex, periventricular white matter, brainstem, cortical atrophy and ventriculomegaly |
| Neuropathology       | Lymphocytic infiltration, inflammation, raised intracranial tension | Periventricular demyelination and inflammation | Inclusion bodies in neurons and glial cells, focal necrosis without inflammation | Cellular inclusion bodies, demyelination, neuronal loss |
| CSF picture          | Marked lymphocytosis with elevated proteins, normal glucose levels | Mild to moderate lymphocytosis with elevated proteins, normal glucose levels | Usually normal, later can show mild pleocytosis or raised proteins | Normal |
| Isolation of         | Can be isolated from brain cells and CSF | Cannot be isolated | Can be isolated | Mutated virus can be isolated |
| measles virus from   |                   |                   |                                   |                                   |
| brain cells          |                   |                   |                                   |                                   |
| Serology             | Measles specific antibodies may or may not be detected in serum and CSF | Myelin basic protein (MBP) is raised in CSF | Rising titers of measles specific antibodies in serum and CSF | Markedly raised measles antibodies in serum and CSF |
| Treatment            | Symptomatic treatment, anticonvulsants, ribavirin | Symptomatic treatment and immunosuppression with steroids, plasmapheresis and IVIG | Symptomatic, ribavirin, interferon alpha | Symptomatic, ribavirin, interferon alpha |

Abbreviations: APME, acute post infectious measles encephalomyelitis; IVIG, intravenous immunoglobulin; MIBE, measles inclusion body encephalitis; PME, primary measles encephalitis; SSPE, sclerosing pan encephalitis.

Encephalitis in Lewis rats following measles infection was found to be associated with cell-mediated T-cell response against MBP. Further, it was suggested that CNS susceptibility to autoimmune T-cell autoimmune reaction increases following CNS infection with measles virus.\(^\text{38}\) It occurs in 1 per 1,000 measles infection which makes measles the most common cause of post infectious ADEM. The highest number of cases are of children 5 years and above, symptoms onset after resolution of rash, even weeks or months later,\(^\text{12,21}\) rarely, it can also predate the rash. The signs and symptoms include abrupt onset of fever, encephalitis (headache, seizures, altered sensorium, raised ICT, and multifocal neurological signs), myelitis (back pain and bladder and bowel dysfunction, and hyporeflexia), ataxia, optic neuritis, and cranial nerve involvement. It has been reported that APME relapses in one-third patients and these patients are at increased risk of developing MS.\(^\text{39,40}\) The preliminary
diagnosis is based on history with clinical examination and it is confirmed with the aid of lab findings – presence of serum IgM/IgG anti-measles antibodies (not in CSF), MRI findings (multifocal hyperintensities in brain and spinal cord on T2 and FLAIR images, brain edema and demyelination) and mild to moderate CSF pleocytosis with elevated protein. Unlike PME the measles virus RNA cannot be detected in CSF or brain cells of APME patients. The treatment is based on the mechanism of disease which is considered to be immune mediated and post infectious. Hence, the goal of treatment is to temper the immune response and not the use of antivirals. Corticosteroids (intravenously followed by oral), intravenous immunoglobulin (IVIG), and plasmapheresis, along with the supportive measures are the recommended treatment options. The prognosis is better than PME and some patients show full recovery, while, some patients showed permanent neurological sequelae along with attention and behavioral issues when evaluated more than 3 years after the episode. Mortality is 5% in children and 25% in adults.

Even with so many differences in pathology, it is sometimes difficult to differentiate whether the patient has PME or APME, because the symptoms of both can occur soon after measles. There may be both factors contributing to the clinical picture including acute viral infection as well as ongoing inflammatory response. However, if the brain imaging shows more edema then patient is treated with steroids.

**Difference between APME and other ADEM:** There are some variations in the ADEM phenotype caused due to measles or other organisms (usually virus). The clinical course of APME is more rapid and severe than other types of ADEM. Cerebellar ataxia most commonly occurs in varicella patients and has better prognosis. The incidence of varicella and rubella-associated ADEM is reported to be much lesser than APME, i.e., 1/10,000 and 1/20,000 cases, respectively. ADEM following an acute pharyngitis (group A beta hemolytic streptococcal infection) has been reported with prominent extrapyramidal and behavioral symptoms.

**APME prevention with measles vaccination:** The incidence of APME or ADEM after measles live vaccine vaccination reduces to one to two cases per million vaccinations, which is significantly lower than among unvaccinated population (Table 1). It will make only 5% of cases amongst all measles-associated ADEM. Also, the clinical phenotype is typically less severe and better recovery than PIE occurs after primary measles infection. However, it has also been suggested that single dose of measles vaccination is not effective in preventing measles and APME. In a study from Vietnam, APME after measles infection was reported in 15 patients (age 20 to 24 year) who had received single dose measles vaccination in infancy. The IgG antibodies titers were raised in all vaccinated patients, and the avidity showed a decreasing trend with an increasing age. Again, it emphasized on the need of second dose of vaccination.

**Measles Inclusion Body Encephalitis**
It is also known as immunosuppressive measles encephalitis and subacute measles encephalitis. MIBE is rare, occurs only in immunocompromised children and adults of any age, with symptoms onset within days to months after measles infection or vaccination. Multiple reports from Texas have described MIBE in total of 33 patients (mean age 6 years) with various immunodeficiency conditions. A report of measles outbreak in South Africa (2009 to 2010) has described eight HIV positive patients (median age 28 years) with MIBE, out of which six patients died and only two survived. Largely, the cases of MIBE have been reported in patients with acute lymphoblastic leukemia and few cases in various malignancies, post transplantation patients, autoimmune disease, HIV infection and recently in stem cell transplantation patient.

The onset of MIBE can occur days to months (within a year) after measles infection or measles vaccination. T-cell function is impaired in immunocompromised patients, hence the typical morbiliform rash (exanthem) as seen in immunocompetent patients is not observed in these patients. Although some have shown a mild rash but without any koplak spots or any other clinical symptoms of primary measles infection. Patients presented with altered sensorium and seizures. Focal seizures along with Todd’s paralysis are the most common types of seizures reported. Epilepsia partialis continua, focal motor deficits (hemiplegia, hemiparesis), aphasia, dysarthria, dysphagia, ataxia, and visual problems can also occur. Headache, vomiting, emotional lability, and autonomic dysfunction have been reported in few cases. It is a rapidly progressive encephalitis leading to coma and death in majority cases.

The neuropathological findings show inclusion bodies in neurons and glial cells, focal necrosis without inflammation. Initial CSF picture is either normal or may show mildly elevated proteins and pleocytosis. However, a four-fold rise in measles antibody in CSF from baseline is observed, as the disease progresses. MRI brain is usually normal but may show edema, enlarged ventricles, and atrophy. In absence of definitive evidence of measles infection, the diagnosis can be confirmed on brain biopsy, by detecting measles virus RNA using reverse transcription polymerase chain reaction or detecting measles hemagglutinin and matrix protein via immunohistochemistry. The brain biopsy tissue of patients shows intracytoplasmic or intranuclear inclusion bodies and hence, the name encephalitis. The treatment of MIBE includes mainly the supportive measures, although a few cases have shown some improvement in symptoms and imaging with ribavirin antiviral therapy, while, interferon-alpha has not shown any efficacy. The prognosis of MIBE is poor, causing mortality in 75% cases and rest are left with neurological sequel.

**Characteristics of MIBE Virus**
The measles virus isolated from brain cells of MIBE patients has shown many mutations in intracytoplasmic domain of F protein. The mutation in L454W of HRC domain has been reported previously which leads to highly unstable F protein with hyper-fusogenicity and thermal labiality. Also, measles virus with this mutation does not require H binding to enter the brain cells. The emergence of virus with L454W mutated
F protein under the selective pressure of fusion inhibitors, raised the question if this neuropathogenic measles virus can be found outside the CNS and spread via natural route. A recent study on mice model has shown respiratory epithelial infection with this measles strain suggesting the possibility of infecting a new host.

On the contrary, sequence analysis of measles virus from 4 MIBE patients has shown similarity with epidemic virus (genotype B3) unlike the typical hypermutation of the matrix and fusion as previously reported. They showed N, M, F, and H genes mutations in unique patterns. Mutation rates in brain were similar to the epidemic virus, although, these mutations were mostly non-synonymous. The function of nucleoprotein gene of measles virus remains same, as this protein helps the virus to move from cell to cell in the brain.

Similar mutations of N gene have been reported in SSPE and MIBE patients, suggesting similarity in two diseases, except the rapid development of MIBE in immunocompromised patients.

MIBE Association and Prevention with Measles Vaccination

MIBE following vaccination has been documented in few cases with ALL and CD8 deficiency, implicated to be caused by vaccine strain with fatal outcomes. Immunosuppressed patients are at higher risk of developing MIBE, but vaccination should not be avoided in all such patients. Children living with lymphoblastic leukemia (remission phase) and post allogeneic bone marrow transplantation patients have been successfully vaccinated for measles without any adverse events. Measles vaccine can be safely given to patients who have been successfully vaccinated with polyvalent human immunoglobulin (within 6 days) with polyvalent human immunoglobulin.

Post exposure prophylaxis (within 6 days) with polyvalent human immunoglobulin should be considered in all immunocompromised patients, even if one has been vaccinated. Lack in the vaccination coverage and non-administration of second dose of vaccine are the two factors contributing to measles infection and its CNS complications in immunocompromised patients.

Subacute Sclerosing Pan Encephalitis

Subacute sclerosing pan encephalitis (SSPE) is a slowly progressive panencephalitis, that is caused by persistence of measles virus which mutates and leads to neurovirulence. The estimated global incidence of SSPE is 4 to 11 cases per lac measles cases, but lesser number of cases are being reported. The incidence is much higher (approximately 18/1,00,000), if measles infection occurs in early childhood. Higher incidence (28 cases per 1,00,000 measles cases) has been reported from developing countries like India and Pakistan. The new cases of SSPE in developed countries now correlate with measles outbreaks. In a recent report of United States, the incidence of SSPE is reported higher (1/609) if measles infection occurs in first year of life while, it decreases (1/1,367) for children under 5 years. The risk of developing SSPE is 16 times higher if measles occurs in infancy as compared to occurring at 5 years or later.

The usual age of presentation ranges from 8 to 11 years but a few cases of SSPE have been reported in toddlers in association with congenital measles. A latent period of 1 to 15 years following primary measles infection has been defined, only recently few cases with shorter latency period have been reported without any evidence of congenital measles. Hence, implicating the need for high index of suspicion for SSPE cases with shorter latency period and presentation at early age. SSPE is often diagnosed late because of the non-specific symptoms at the onset, including behavioral problems like inattention, forgetfulness, temper tantrums, and decline in scholastic performance. It is much later that the motor dysfunction and intellectual dysfunction become apparent. Patients typically has myoclonic jerks (typically periodic, generalized, and stereotype), dyskinesia, and ataxia. Later, expressive speech decreases progressively along with difficulty in walking and tone abnormalities, finally leading to vegetative state.

In nearly half of the SSPE patients, ocular manifestations have been reported, most common being necrotizing chorioretinitis. However, macular edema/degeneration, optic neuritis/atrophy, papillitis/papilledema, and cortical blindness can also occur. The neuropathological findings in SSPE depend on the course of the disease. During early disease, edema is the predominant finding, followed by oxidative damage of DNA and RNA in infected cells along with lipid peroxidation in areas of demyelination. Perivascular infiltration of inflammatory cells and demyelination in cortical and subcortical are found in acute phase followed by neuronal loss later. The inflammation starts from the posterior brain with medial thalamus and deep structures involvement followed by anterior brain involvement.

CSF examination is generally normal but sometimes may show mildly elevated proteins. The gold standard for diagnosing SSPE has raised IgM and IgG anti-measles antibodies in CSF and serum, higher titers in CSF. EEG generally shows specific burst suppression pattern which deteriorates to diffuse slow waves with the progression of disease. MRI brain picture can vary from decreased grey matter volume to hyperintensities in cerebral cortex, periventricular white matter, and brainstem leading to cortical atrophy and enlarged ventricles in last stage.

Supportive care and symptomatic management are the mainstays of treatment for SSPE which include anticonvulsants and spasticity reducing drugs. Trials with few drugs like isoprinosine and interferon alpha have shown some benefits of therapy in terms of slower progression, temporary stabilization and prolonged survival. While, ribavirin and immunoglobulin have shown little effects, mesenchymal stem cell treatment has demonstrated no benefit in SSPE patients.
Atypical Presentation of SSPE

There are few reported cases of SSPE with largely or exclusively involving brainstem and presenting with symptoms like cerebellar ataxia, blindness, choreoathetoid movements of extremities. The neuroimaging of these patients showed pons, middle cerebellar peduncles, midbrain, substantia nigra, and inferior colliculus involvement while other areas still spared. These cases can be misdiagnosed as isolated demyelinating syndrome. Rarely SSPE may present with an acute-fulminant disease with rapid course of disease leading to death, within 6 months. It is difficult to differentiate acute fulminant SSPE from ADEM and diagnose early. It has also been reported during pregnancy and postpartum, with least reported time to death after diagnosis to be 19 days.

Characteristics of SSPE Virus

A variety of genetic mutations have been reported in measles virus isolated from SSPE patients brain tissue. It has been suggested that genetic mutations occur only after virus enters the brain. The characteristic clustered mutation is biased hypermutation, leading to uracil to cytosine transitions in M gene. Another study reported mutation in 2% of nucleotides in SSPE virus, which led to 35% changes in amino acids. Defects in M proteins help the virus for replication and persistence in neuronal cells while evading the neutralizing antibodies. Genetic mutation in F gene leads to hyperfusogenic F protein, which enables measles virus for neuronal spread. Many mutations have been reported which facilitate cell to cell fusion without SLAM or nectin 4 receptors. Similarly, many mutations reported in H protein help in virus spread among neurons.

SSPE Prevention with Measles Vaccination

Since the introduction of measles vaccination, number of SSPE cases have reduced drastically, but in developing countries like India, due to lower vaccination coverage, number of SSPE cases are still high. None of the studies or epidemiological surveys have shown SSPE due to vaccine strain measles virus. It is suggested that, SSPE patients who do not have history of prior measles infection, might have had subclinical or undiagnosed measles in early childhood. In a child with SSPE, who has received measles vaccine, wild measles infection is presumed to occur before vaccination. Re-emergence of SSPE cases in developed countries coincides with measles outbreaks. In a study from California, higher rates of SSPE were reported in unvaccinated children, mainly those who acquired infection during first year of life.

Association of Measles Vaccine Virus with CNS-Related Measles Complications

There have been concerns regarding measles vaccine virus causing measles-related CNS complications. Few cases of encephalitis in healthy individuals, and a couple of MIBE case reports in immunocompromised patients (ALL and HIV), and some cases of SSPE have been attributed to vaccination, in whom there was no history of prior clinical measles infection. However, the possibility of wild type measles virus infection cannot be ruled out in these cases.

Some authors have implicated the vaccine virus to cause acute encephalitis in many cases solely on the basis of temporal association (onset of symptoms within 6 to 15 days of vaccination). In one of these cases, measles virus was isolated from CSF on ninth day of vaccination. On the basis of infectivity titer, tissue culture sensitivity, and plaquing, it was indicated that the isolate was vaccine like virus, however, genetic sequencing was not performed. Epidemiological data demonstrate that the rate of acute encephalitis within 15 to 30 days of measles vaccination is comparable to the expected background encephalitis rate. However, a clustering of cases on days 8 and 9 post vaccination suggested a possible causal relationship. To date, there have been no reports of genetic sequences characteristic of measles vaccine strains in cases of acute encephalitis.

Amongst reported cases of vaccine-associated MIBE, vaccine like virus was isolated from the brain tissue of a 21-month-old boy, who had primary immunodeficiency. The nucleotide sequence of isolated virus was identical to that of the Moraten and Schwarz vaccine strains in the nucleoprotein and fusion gene regions while, the fusion gene was different from wild-type genotype A virus, implicating vaccine virus as the cause of MIBE. However, authors also suggested that such an adverse event is very rare and the report should not lead to changes in current immunization practice.

According to the report of GACVS (Global Advisory Committee On Vaccine Safety) meeting 2005, the available epidemiological and measles virus genotyping data, do not suggest that measles vaccine virus can cause SSPE. Furthermore, measles vaccine can neither trigger/accelerate the course of SSPE in an unvaccinated individual nor can lead to the development of SSPE in a person who had benign persistent wild measles infection at the time of vaccination. Also, the available evidence points to natural subclinical measles infection as the cause of SSPE in vaccinated individuals, who had no previous history of prior measles infection. In a report on 81 children with confirmed SSPE, 17 children did not report past history of measles infection or vaccination. This suggests the phenomenon of subclinical measles leading to SSPE. Till date, no genetic similarity of the defective measles virus in the brain tissue of SSPE cases has been shown with the attenuated measles vaccine virus, hence, there is no evidence to believe that measles vaccine may cause SSPE.

Summary

Measles is a vaccine preventable disease, still the measles infection rates are high amongst developing countries leading to significant morbidity and mortality. The neurological complications of measles infection can occur within days, months, or years later. The varied presentation and pathology of these complications sometimes pose difficulties in diagnosis and
management as well. Many mutations have been detected in various genes of measles virus which are implicated for the persistence and tropism of virus in the brain. The newer therapeutic options are based on these mutations and are currently under research. Timely diagnosis and supportive treatment still remain the first line of treatment. Adequate vaccination of population with two doses of measles vaccine is the only preventive measure and should be undertaken.

**Conflict of Interest**
None declared.

**References**

1. Ferreira CSA, Frenzke M, Leonard VHJ, Welstead GG, Richardson CD, Cattaneo R. Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). J Virol 2010;84(06):3033–3042
2. Frenzke M, Sawatsky B, Wong XX, et al. Nectin-4-dependent measles virus spread to the cytomolgus monkey tracheal epithelium: role of infected immune cells infiltrating the lamina propria. J Virol 2013;87(05):2526–2534
3. Sindhu TG, Geeta MG, Krishnakumar P, Sabitha S, Ajina KK. Clinical profile of measles in children with special reference to infants. Trop Doct 2019;49(01):20–23
4. Ben-Chetrit E, Öster Y, Jarjou L, et al. Measles-related hospitalizations and associated complications in Jerusalem, 2018–2019. Clin Microbiol Infect 2020;26(05):637–642
5. Marie JC, Sattle F, Escala JM, Juric P, Wild TF, Horvat B. Cell surface delivery of the measles virus nucleoprotein: a viral strategy to induce immunosuppression. J Virol 2004;78(21):11952–11961
6. Moss WJ, Griffin DE. Lancet 2012;379(9811):153–164
7. Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol 2009;38(01):192–205
8. World Health Organization. Progress towards regional measles elimination worldwide, 2000–2017. Wkly Epidemiol Rec 2018;9:649–660
9. Strebel PM, Orenstein WA. Measles. N Engl J Med 2019;381(04):349–357
10. World Health Organization. Immunization, vaccines and biologicals: new measles surveillance data for 2019
11. World Health Organization. Ten threats to global health in 2019.
12. Miller DL. Frequency of complications of measles, 1963. Report on a national inquiry by the public health laboratory service in collaboration with the society of medical officers of health. BMJ 1964;2(5401):75–78
13. Reuter D, Schneider-Schaulies J. Measles virus infection of the CNS: human disease, animal models, and approaches to therapy. Med Microbiol Immunol (Berl) 2010;199(03):261–271
14. Pratapkiriya W, Ping Teh AP, Radtanaatikahanon A, et al. Expression of canine distemper virus receptor nectin-4 in the central nervous system of dogs. Sci Rep 2017;7(01):349
15. Pratapkiriya W, Seki F, Otsuki N, et al. Nectin4 is an epithelial cell receptor for canine distemper virus and involved in neurovirulence. J Virol 2012;86(18):10207–10210
16. Generous AR, Harrison OJ, Troyanovsky RB, et al. Trans-endocytosis elicited by nectins transfers cytoplasmic cargo, including infectious material, between cells. J Cell Sci 2019;132(16):jcs235507
17. Ferren M, Horvat B, Mathieu C. Measles encephalitis: towards new therapeutics. Viruses 2019;11(11):1017
18. Watanabe S, Shirogane Y, Sato Y, Hashiguchi T, Yanagi Y. New insights into measles virus brain infections. Trends Microbiol 2019;27(02):164–175
19. Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles viruses host invasion and pathogenesis. Viruses 2016;8(08):210
20. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol 2007;28(01):5–11
21. Buchanan R, Bonthius DJ. Measles viruses and associated central nervous system sequelae. Semin Pediatr Neurol 2012;19(03):107–114
22. Cherry JD, Harrison GJ, Kaplan SL, Hotze PJ, Steinbach WJ, Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 2014
23. Gendelman HE, Wolinsky JS, Johnson RT, Pressman NJ, Pezeshkpour GH, Boisset GF. Measlesencephalomyelitis: lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination. Ann Neurol 1984;15(04):353–360
24. ter Meulen V, Müller D, Käckell Y, Katz M, Meyermann R. Isolation of infectious measles virus in measles encephalitis. Lancet 1972;2(7788):1172–1175
25. Esolen LM, Takahashi K, Johnson RT, et al. Brain endothelial cell infection in children with acute fatal measles. J Clin Invest 1995;96(05):2478–2481
26. Hosoya M. Measles encephalitis: direct viral invasion or autoimmune mediated inflammation? Intern Med 2006;45(14):841–842
27. Johnson RT, Griffin DE, Hirsch RL, et al. Measlesencephalomyelitis—clinical and immunologic studies. N Engl J Med 1984;310(03):137–141
28. Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993;16(05):654–660
29. Forni Al, Schluger NW, Roberts RB. Severe measles pneumonia in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994;19(03):454–462
30. Pickering LK, Baker CJ, Long SS, McMillan JA. Measles: American Academy of Pediatrics, Red Book. Report of the Committee on Infectious Diseases. 2006;27:441–452
31. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004;189(suppl 1):54–516
32. Ota MO, Moss WJ, Griffin DE. Emerging diseases: measles. J Neurovirol 2005;11(05):447–454
33. Fisher DL, Defres S, Solomon T. Measles-induced encephalitis. QJM 2015;108(03):177–182
34. Mayer MC, Meinel E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord 2012;5(03):147–159
35. O’Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13(02):211–217
36. ’t Hart BA, Hintzen RQ, Laman JD. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 2008;5(01):38–52
37. ’t Hart BA, Hintzen RQ, Laman JD. Multiple sclerosis – a response-to-damage model. Trends Mol Med 2009;15(06):235–244
38. Liebert UG, Hashim GA, ter Meulen V. Characterization of measles virus-induced cellular autoimmune reactions against myelin basic protein in Lewis rats. J Neuroimmunol 1990;29(1-3):139–147
39. Banwell BL. Acquired demyelination of the central nervous system. In: Maria B, ed. Current Management in Child Neurology. 200503486–493
Menge T, Kieser T, Nessler S, Hemmer B, Hartung HP, Stöve O. Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol 2007;20(03):247–254

Tenembaum S, Chitnis T, Ness J, Hahn JS, Group IJMPSInternational Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007;68(16, suppl 2):S23–S36

Bennetto L, Scolding N. Inflammatory/post-infectious encephalomyelitis. J Neurol Neurosurg Psychiatry 2004;75(Suppl 1):i22–i28

Chowdhary J, Ashraf SM, Khajuria K. Measles with acute disseminated encephalomyelitis (ADEM). Indian Pediatr 2009;46(01):72–74

Fox A, Hung TM, Wertheim H, et al. Acute measles encephalitis in partially vaccinated adults. PLoS One 2013;8(08):e71671

Albertyn C, Schaaf KP, Haji-Kian K. Measles virus in the brains of patients with measles inclusion body encephalitis. Arch Dis Child 1993;68(06):775–778

Freeman AF, Jacobsohn DA, Shulman ST, et al. A new complication of stem cell transplantation: measles inclusion body encephalitis. Pediatrics 2004;114(05):e565–e566

Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999;29(04):855–861

Hardie DR, Albertyn C, Heckmann JM, Smuts HEM. Molecular characterisation of virus in the brains of patients with measles inclusion body encephalitis (MIBE). Virol J 2013;10:283

Mathieu C, Ferren M, Jurgens E, et al. Mutations in the fusion protein of measles virus that confer resistance to the membrane fusion inhibitors carbobenzoxy-D-Phe-L-Phe-Gly and 4-nitro-2-phenylacetyl amino-benzamide. J Virol 2017;91(23):e01026–e17

Rima BK, Duprex WP. Molecular mechanisms of measles virus persistence. Virus Res 2005;111(02):132–147

Ohuchi M, Ohuchi R, Mifune K, Ishihara T, Ogawa T. Characterization of the measles virus isolated from the brain of a patient with immunocompromise. J Infect Dis 1987;156(03):436–441

Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child 1962;103:413–418

Valmari P, Lanning M, Tuokko H, Kouvalainen K. Measles virus in the cerebrospinal fluid in postvaccination immunosuppressive measles encephalopathy. Pediatr Infect Dis J 1987;6(01):59–63

Baldoli A, Dargère S, Cardineau E, et al. Measles inclusion-body encephalitis (MIBE) in a immunocompromised patient. J Clin Virol 2016;81:43–46

Antona D, Lévy-Bruhl D, Baudon C, et al. Measles elimination efforts and 2008-2011 outbreak, France. Emerg Infect Dis 2013;19(03):357–364

Mclean HF, Fiebelkorn AP, Temte JL, Wallac GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and mortality weekly report Recommendations and reports/centers for Disease Control 2013;62 (RR-04):1–34

Wendorff KA, Winter K, Zipprich J, et al. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clin Infect Dis 2017;65(02):226–232

World Health Organization. Weekly epidemiological record. No. 2, 2006, 81, 13–20

Simşek E, Oztürk A, Yavuz C, Kocabay K. Subacute sclerosing panencephalitis (SSPE) associated with congenital measles infection. Turk J Pediatr 2005;47(01):58–62

Zwiauer K, Forstenpointner E, Popow-Kraupp T, Hauser E, Jellinger KA. Rapid progressive subacute subcortical panencephalitis after perinatally acquired measles virus infection. Lancet 1995;345(8957):1124

Dasopolou M, Covans A. Subacute sclerosing panencephalitis after intrauterine action. Acta Paediatr 2004;93(09):1251–1253

Saurabh K, Gupta R, Khare S, Sharma S. Atypical subcortical scle- rosepanencephalitis with short onset latency. Indian Pediatr 2013;50(02):244–245

Aulakh R, Tiwari A. Subacute sclerosing panencephalitis in a toddler: changing epidemiological trends. Case Rep Pediatr 2013;2013:341462

Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol 2010;52(10):901–907

Babu RB, Biswas J. Bilateral macular retinitis as the presenting feature of subacute sclerosing panencephalitis. J Neuroophthal-mol 2007;27(04):288–291

Chiiodi F, Sundqvist VA, Norbye E, Mavra M, Link H. Measles IgM antibodies in cerebrospinal fluid and serum in subacute scle- rosepanencephalitis. J Med Virol 1986;18(02):149–158

Kiessling WR, Hall WW, Yung LL, ter Meulen V. Measles-virus-specific immunoglobulin-M response in subacute sclerosing panencephalitis. Lancet 1977;1(8007):324–327

Bonthius DJ, Stanek N, Grose C. Subacute sclerosing panencephalitis, a measles complication, in an internationally adopted child. Emerg Infect Dis 2000;6(04):377–381

Garg RK. Subacute sclerosing panencephalitis. J Neurol 2008;255 (12):1861–1871

Anlar B, Aydin OF, Guven A, Sonmez FM, Kose G, Herguner O. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. J Neurol 2004;251(11):1890–1894

Saini AG, Sankhyan N, Padmanabh H, Sahu JK, Vyas S, Singh P. Subacute sclerosing panencephalitis presenting as acute cerebel- lar ataxia and brain stem hyperintensities. Eur J Paediatr Neurol 2016;20(03):435–438

Kumar N, Ranjan A, Kumar A, Kumar B. Teaching Neurolimages: isolated pontine involvement in subacute sclerosing panencephalitis. Neurology 2018;91(03):e293–e294

Singhi P, Saini AG, Sankhyan N, Gupta P, Vyas S. Blindness, dancing extremities, and corpus callosum and brain stem involvement: an unusual presentation of fulminant subacute sclerosing panencephalitis. J Child Neurol 2015;30(01):87–90

Garg RK, Mahadevan A, Malhotra HS, Rizvi I, Kumar N, Uniyal R. Subacute sclerosing panencephalitis. Rev Med Virol 2019;29(05):e2058

Mahadevan A, Vaidya SR, Wairagkar NS, et al. Case of fulminant-SSPE associated with measles genotype D7 from India: an autopsy study. Neuropathology 2008;28(06):621–626

Cattaneo R, Schmid A, Eschle B, Baczko K, ter Meulen V, Billeter MA. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 1988;55(02):255–265

Patterson JB, Cornu TI, Redwine J, et al. Evidence that the hyper- mutated M protein of a subacute sclerosing panencephalitis measles virus actively contributes to the chronic progressive CNS disease. Virology 2001;291(02):215–225

Kweder H, Alouze M, Cosby SL, et al. Mutations in the H, F, or M proteins can facilitate resistance of measles virus to neutralizing human anti-MV sera. Adv Virol 2014;2014:205617

Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007;36(06):1334–1348
Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192(10):1686–1693

Landrigan PJ, Witte JJ. Neurologic disorders following live measles-virus vaccination. JAMA 1973;223(13):1459–1462

Weibel RE, Caserta V, Benor DE, Evans G. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 1998;101(3 Pt 1):383–387

Encephalitis Surveillance, 1965 Annual Summary. Atlanta: National Communicable Disease Center; 1966:15

Belgamwar RR, Prasad S, Appaya P. Measles, mumps, rubella vaccine induced subacute sclerosing panencephalitis. J Indian Med Assoc 1997;95(11):594

Weekly Epidemiological Record. 2006, vol. 81, 02

Saha V, John TJ, Mukundan P, et al. High incidence of subacute sclerosing panencephalitis in south India. Epidemiol Infect 1990; 104(01):151–156

John T. Measles vaccination and risk of SSPE – reply. Indian Pediatr 1999;36(03):318